International activities: business delegation trip to China
Following the very successful biotech trip in 2010, the Federal Ministry of Economics and Technology and the German economic development agency Germany Trade & Invest (GTAI) have asked Brücke Osteuropa (the German Association for Economic and Technological Cooperation with Eastern Europe and Asia) and BIO Deutschland to organise a second cooperation trip to China for the sector.
This trip will take place from 14 to 21 May 2011 as part of the Federal Economics Ministry’s programme of information and networking trips. It is aimed at companies and institutes in the biotechnology, pharmaceutics and medical technology sectors. The focus will be on opportunities for economic and technological cooperation with the biotechnology industry bases in Beijing and in Guangzhou and Shenzhen in the southern Chinese province of Guangdong. The programme will include a German-Chinese cooperation meeting and visits to companies and institutes.
As the cooperation trip will coincide with the trade fair CECIA China Exhibition & Conference on Instrumental Analysis & Biotechnology (www.chinacecia.com/en), which will be held in Guangzhou from 16 to 18 May, the programme will also include a visit to the fair.
Companies and research institutes that are active in biotechnology and its many applications, particularly environmental protection, pharmaceutics, medical technology, agriculture and food technology, are invited to join the delegation. Other related sectors, especially equipment manufacturing, measuring and laboratory technology, bioinformatics and similar fields are also very welcome.
China is increasingly investing in new technologies, including biotechnology, pharmaceutics and medical technology. In recent years, the country has made great efforts in these sectors and has also achieved its first major results. A national development programme for the biotech industry was implemented as part of the five-year plan from 2006 to 2010. Since 2005, 22 national biotech industry bases have been set up nationwide in several stages by the National Development and Reform Commission. The latest five-year plan means that higher standards of quality can be expected in all areas of health care in the Chinese pharmaceutical sector. In addition, the plan aims to improve the conditions (such as better legal certainty, simplified regulations and procedures, tax incentives) for joint ventures, foreign R&D and M&A activities.
You will find further information and an overview of biotechnology in China on the website www.eastbridge.de/Biotech-China.
The fee of €2,120 for the trip includes participation in the entire programme, return flights from Munich to Beijing with Air China, train transfers to Munich, domestic flights within China, visa fees, hotels and the meals listed in the programme.